{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:35:54Z","timestamp":1780374954001,"version":"3.54.1"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.5888","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T15:36:16Z","timestamp":1590593776000},"page":"e205888","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of the Cost-effectiveness of Services for Schizophrenia in the UK Across the Entire Care Pathway in a Single Whole-Disease Model"],"prefix":"10.1001","volume":"3","author":[{"given":"Huajie","family":"Jin","sequence":"first","affiliation":[{"name":"King\u2019s Health Economics, Institute of Psychiatry, Psychology, and Neuroscience, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Tappenden","sequence":"additional","affiliation":[{"name":"Health Economics and Decision Science, University of Sheffield School of Health and Related Research, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"MacCabe","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Robinson","sequence":"additional","affiliation":[{"name":"Loughborough University School of Business and Economics, Loughborough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Byford","sequence":"additional","affiliation":[{"name":"King\u2019s Health Economics, Institute of Psychiatry, Psychology, and Neuroscience, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"zoi200278r2","doi-asserted-by":"crossref","DOI":"10.1007\/s40273-020-00895-6","article-title":"A systematic review of economic models across the entire schizophrenia pathway.","author":"Jin","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"zoi200278r3","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.jval.2012.07.008","article-title":"Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework.","volume":"15","author":"Tappenden","year":"2012","journal-title":"Value Health"},{"issue":"5","key":"zoi200278r5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40273-013-0032-y","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.","volume":"31","author":"Husereau","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"zoi200278r6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.eurpsy.2012.08.002","article-title":"Outreach and support in south London (OASIS), 2001-2011: ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis.","volume":"28","author":"Fusar-Poli","year":"2013","journal-title":"Eur Psychiatry"},{"issue":"12","key":"zoi200278r11","article-title":"Crisis intervention for people with severe mental illnesses.","author":"Murphy","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi200278r12","first-page":"365","article-title":"Four-year cost-effectiveness of cognitive behavior therapy for preventing first-episode psychosis: the Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial.","volume":"43","author":"Ising","year":"2017","journal-title":"Schizophr Bull"},{"issue":"1","key":"zoi200278r13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1017\/S1121189X00001469","article-title":"Economic evaluation of a crisis resolution service: a randomised controlled trial.","volume":"18","author":"McCrone","year":"2009","journal-title":"Epidemiol Psichiatr Soc"},{"issue":"432","key":"zoi200278r14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/acp.2006.114.issue-s432","article-title":"Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain.","volume":"432","author":"Gutierrez-Recacha","year":"2006","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"6","key":"zoi200278r15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1478-7547-9-6","article-title":"Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia.","volume":"9","author":"Phanthunane","year":"2011","journal-title":"Cost Eff Resour Alloc"},{"key":"zoi200278r16","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1080\/17441692.2014.986158","article-title":"Schizophrenia interventions in Vietnam: primary results from a cost-effectiveness study.","volume":"10","author":"Anh","year":"2015","journal-title":"Glob Public Health"},{"key":"zoi200278r17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1192\/bjp.162.1.38","article-title":"Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom.","volume":"162","author":"Davies","year":"1993","journal-title":"Br J Psychiatry"},{"issue":"4","key":"zoi200278r19","first-page":"199","article-title":"Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.","volume":"8","author":"Oh","year":"2001","journal-title":"Can J Clin Pharmacol"},{"issue":"1","key":"zoi200278r20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1192\/bjpo.bp.115.002576","article-title":"Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials.","volume":"2","author":"Zhao","year":"2016","journal-title":"BJPsych Open"},{"issue":"9896","key":"zoi200278r21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"zoi200278r22","article-title":"Family intervention (brief) for schizophrenia.","author":"Okpokoro","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi200278r1","volume-title":"Guide to the Methods of Technology Appraisal","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"zoi200278r4","volume-title":"Using Whole Disease Modelling to Inform Resource Allocation Decisions in Schizophrenia Services","author":"Jin","year":"2019"},{"key":"zoi200278r9","volume-title":"Computer Simulation in Management Science","author":"Pidd","year":"2006","edition":"5th ed"},{"key":"zoi200278r7","unstructured":"National Institute of Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Updated March 1, 2014. Accessed April 29, 2020. https:\/\/www.nice.org.uk\/guidance\/cg178"},{"key":"zoi200278r8","unstructured":"National Institute of Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. Updated October 26, 2016. Accessed April 29, 2020. https:\/\/www.nice.org.uk\/guidance\/cg155"},{"key":"zoi200278r10","unstructured":"Davis? S, Stevenson? M, Tappenden? P, Wailoo? AJ. NICE DSU Technical Support Document 15: cost-effectiveness modelling using patient-level simulation. Published April 2014. Accessed September 9, 2018. http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD15_Patient-level_simulation.pdf"},{"key":"zoi200278r18","unstructured":"Glennie? J. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Updated January 1, 1997. Accessed April 29, 2020. https:\/\/www.cadth.ca\/pharmacoeconomic-evaluations-clozapine-treatment-resistant-schizophrenia-and-risperidone-chronic-0"},{"key":"zoi200278r23","unstructured":"NHS Digital. Prescription Cost Analysis: England, 2016. Published March 30, 2017. Accessed March 3, 2016. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/prescription-cost-analysis\/prescription-cost-analysis-england-2016"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2766240\/jin_2020_oi_200278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T15:36:28Z","timestamp":1590593788000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2766240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.5888","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]}}}